HUP0001063A2 - Zöld porfirinek alkalmazása ateroszklerózis kezelésére szolgáló gyógyászati készítmények előállítására - Google Patents
Zöld porfirinek alkalmazása ateroszklerózis kezelésére szolgáló gyógyászati készítmények előállításáraInfo
- Publication number
- HUP0001063A2 HUP0001063A2 HU0001063A HUP0001063A HUP0001063A2 HU P0001063 A2 HUP0001063 A2 HU P0001063A2 HU 0001063 A HU0001063 A HU 0001063A HU P0001063 A HUP0001063 A HU P0001063A HU P0001063 A2 HUP0001063 A2 HU P0001063A2
- Authority
- HU
- Hungary
- Prior art keywords
- manufacture
- green
- inhibiting
- development
- preventing
- Prior art date
Links
- 150000004032 porphyrins Chemical class 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 210000001367 artery Anatomy 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000012876 carrier material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A találmány tárgyát érlerakódás kifejlődésének gátlására vagymegelőzésére alkalmas gyógyászati készítmény és ennek alkalmazásaképezi, ahől a készítmény a) valamely zöld pőrfirin dózisegységéttartalmazza az érlerakódás kifejlődésének gátlására vagy megelőzésérealkalmas hatásős mennyiségben, ahől e dózist szándékős fénybesűgárzásmellőzésével adják be, b) és gyógyászatilag megfelelő segéd- ésvivőanyagőkat tartalmaz. A találmány szerinti zöld pőrfirintartalmúkészítmények hatásősan gátőlják az artéria falán keletkezőzsírlerakódásők, főltők képződését az esetben is, ha a kezelésnél nemalkalmaznak szándékősan fénybesűgárzást. ŕ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/663,890 US5834503A (en) | 1996-06-14 | 1996-06-14 | Methods to treat arterial plaque |
PCT/CA1997/000393 WO1997048393A1 (en) | 1996-06-14 | 1997-06-05 | Use of green porphyrins in the manufacture of a medicament in the treatment of atherosclerosis without purposeful irradiation of the porphyrin derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0001063A2 true HUP0001063A2 (hu) | 2000-09-28 |
HUP0001063A3 HUP0001063A3 (en) | 2001-02-28 |
Family
ID=24663656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0001063A HUP0001063A3 (en) | 1996-06-14 | 1997-06-05 | Use of green porphyrins in the manufacture of a medicament treating atherosclerosis |
Country Status (13)
Country | Link |
---|---|
US (2) | US5834503A (hu) |
EP (1) | EP0910371A1 (hu) |
JP (1) | JP2000512300A (hu) |
KR (1) | KR20000016656A (hu) |
CN (1) | CN1101188C (hu) |
AR (1) | AR008392A1 (hu) |
AU (1) | AU714045B2 (hu) |
CA (1) | CA2257564A1 (hu) |
HU (1) | HUP0001063A3 (hu) |
NO (1) | NO985829L (hu) |
NZ (1) | NZ333236A (hu) |
TW (1) | TW514527B (hu) |
WO (1) | WO1997048393A1 (hu) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834503A (en) * | 1996-06-14 | 1998-11-10 | Qlt Phototherapeutics, Inc. | Methods to treat arterial plaque |
DE19824653A1 (de) * | 1998-02-25 | 1999-08-26 | Schering Ag | Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie |
US6331235B1 (en) * | 1998-12-11 | 2001-12-18 | The University Of British Columbia | Chiral separation of benzoporphyrin derivative mono-and di-acids by laser-induced fluorescence capillary electrophoresis |
US6609014B1 (en) * | 1999-04-14 | 2003-08-19 | Qlt Inc. | Use of PDT to inhibit intimal hyperplasia |
US7022843B1 (en) | 1999-04-14 | 2006-04-04 | The University Of British Columbia | β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
US20040229295A1 (en) * | 1999-05-17 | 2004-11-18 | Marchitto Kevin S. | Activated delivery of biomolecules using electromagnetic energy |
US20040208855A1 (en) * | 1999-11-17 | 2004-10-21 | Allison Beth Anne | Use of PDT to inhibit intimal hyperplasia |
US6750037B2 (en) | 1999-12-27 | 2004-06-15 | Edwin L. Adair | Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques |
US6984498B2 (en) * | 1999-12-27 | 2006-01-10 | Adair Edwin L | Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques |
AU2002233092A1 (en) | 2001-02-15 | 2002-08-28 | Qlt Inc. | Reduction or prevention of pdt related inflammation |
US6790463B2 (en) * | 2001-03-30 | 2004-09-14 | Robert F. Hofmann | Uses of targeted oxidative therapeutic formulation in arteriosclerosis |
US20030103995A1 (en) * | 2001-06-04 | 2003-06-05 | Hamblin Michael R. | Detection and therapy of vulnerable plaque with photodynamic compounds |
EP1374912B1 (en) * | 2002-06-21 | 2006-08-16 | Edwin L. Adair | Use of metaloporphyrins for treatment of arteriosclerotic lesions |
US20080260650A1 (en) * | 2004-10-28 | 2008-10-23 | The General Hospital Corporation | Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation |
WO2006049599A1 (en) * | 2004-10-28 | 2006-05-11 | The General Hospital Corporation | Methods of detection and therapy for atheromatous plaques using immune modulation |
US8109981B2 (en) | 2005-01-25 | 2012-02-07 | Valam Corporation | Optical therapies and devices |
US20070299431A1 (en) * | 2006-05-02 | 2007-12-27 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
US7465312B2 (en) | 2006-05-02 | 2008-12-16 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
PE20110591A1 (es) | 2008-07-28 | 2011-09-15 | Takeda Pharmaceutical | Composicion farmaceutica estabilizada a base de un compuesto no peptidico |
US7968127B2 (en) * | 2008-07-28 | 2011-06-28 | Winslow David E | Reverse vitamin K effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets |
CN115054703B (zh) * | 2022-06-30 | 2023-08-04 | 东南大学 | 具有近红外光响应性和靶向性的脂质体、制备方法及应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4577636A (en) * | 1982-11-23 | 1986-03-25 | The Beth Israel Hospital Association | Method for diagnosis of atherosclerosis |
US4512762A (en) * | 1982-11-23 | 1985-04-23 | The Beth Israel Hospital Association | Method of treatment of atherosclerosis and a balloon catheter for same |
US5171749A (en) * | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5095030A (en) * | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US4920143A (en) * | 1987-04-23 | 1990-04-24 | University Of British Columbia | Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents |
US5283255A (en) * | 1987-01-20 | 1994-02-01 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
US5129396A (en) * | 1988-11-10 | 1992-07-14 | Arye Rosen | Microwave aided balloon angioplasty with lumen measurement |
US5214036A (en) | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
US5053423A (en) * | 1990-03-22 | 1991-10-01 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
EP0650368A1 (en) * | 1992-06-24 | 1995-05-03 | Cortex Pharmaceuticals, Inc. | Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity |
US5422362A (en) * | 1993-07-29 | 1995-06-06 | Quadra Logic Technologies, Inc. | Method to inhibit restenosis |
DE69434598T3 (de) * | 1993-07-29 | 2010-07-29 | The United States Of America Represented By The Secretary, Department Of Health And Human Services | Verwendung von Paclitaxel und seinen Derivaten zur Herstellung eines Medikaments für die Behandlung von Restenose |
US5789433A (en) * | 1995-01-17 | 1998-08-04 | Quadra Logic Technologies, Inc. | Green porphyrins as immunomodulators |
US5834503A (en) * | 1996-06-14 | 1998-11-10 | Qlt Phototherapeutics, Inc. | Methods to treat arterial plaque |
-
1996
- 1996-06-14 US US08/663,890 patent/US5834503A/en not_active Expired - Fee Related
-
1997
- 1997-06-05 CN CN97195509A patent/CN1101188C/zh not_active Expired - Fee Related
- 1997-06-05 WO PCT/CA1997/000393 patent/WO1997048393A1/en not_active Application Discontinuation
- 1997-06-05 NZ NZ333236A patent/NZ333236A/en unknown
- 1997-06-05 JP JP10501989A patent/JP2000512300A/ja active Pending
- 1997-06-05 KR KR1019980710255A patent/KR20000016656A/ko not_active Application Discontinuation
- 1997-06-05 EP EP97923698A patent/EP0910371A1/en not_active Withdrawn
- 1997-06-05 CA CA002257564A patent/CA2257564A1/en not_active Abandoned
- 1997-06-05 HU HU0001063A patent/HUP0001063A3/hu unknown
- 1997-06-05 AU AU29470/97A patent/AU714045B2/en not_active Ceased
- 1997-06-13 AR ARP970102602A patent/AR008392A1/es not_active Application Discontinuation
- 1997-07-26 TW TW086110758A patent/TW514527B/zh active
-
1998
- 1998-11-09 US US09/188,583 patent/US6235767B1/en not_active Expired - Fee Related
- 1998-12-11 NO NO985829A patent/NO985829L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU714045B2 (en) | 1999-12-16 |
CN1222076A (zh) | 1999-07-07 |
NO985829L (no) | 1999-02-11 |
EP0910371A1 (en) | 1999-04-28 |
AR008392A1 (es) | 2000-01-19 |
US5834503A (en) | 1998-11-10 |
CN1101188C (zh) | 2003-02-12 |
AU2947097A (en) | 1998-01-07 |
NO985829D0 (hu) | 1998-12-11 |
JP2000512300A (ja) | 2000-09-19 |
KR20000016656A (ko) | 2000-03-25 |
NZ333236A (en) | 2000-06-23 |
HUP0001063A3 (en) | 2001-02-28 |
TW514527B (en) | 2002-12-21 |
US6235767B1 (en) | 2001-05-22 |
CA2257564A1 (en) | 1997-12-24 |
WO1997048393A1 (en) | 1997-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0001063A2 (hu) | Zöld porfirinek alkalmazása ateroszklerózis kezelésére szolgáló gyógyászati készítmények előállítására | |
NO20014842D0 (no) | Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft | |
BR9306841A (pt) | Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico | |
ATE319447T1 (de) | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen | |
NO931267L (no) | Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin | |
PT913156E (pt) | Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia | |
BR0012136A (pt) | Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos | |
BR0113447A (pt) | Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica | |
FI922325A0 (fi) | Oral sammansaettning foer botning av inflammatoriska tarmkanalsjukdomar. | |
MX9302038A (es) | Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s. | |
EA199900499A1 (ru) | Фармацевтическая композиция, включающая соединение, обладающее анти-xa активностью, и соединение антагонист агрегации тромбоцитов | |
DE69426334D1 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
DK47089D0 (da) | Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer | |
EA200000176A1 (ru) | Применение физиологически приемлемых соединений, солей и комплексов ванадия | |
KR970061244A (ko) | 치매 치료용 약학 조성물 | |
RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
CZ20011550A3 (cs) | Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití při léčbě vaskulárních onemocnění a farmaceutické kompozice ho obsahující | |
KR970704442A (ko) | 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia) | |
WO1997026880A3 (en) | Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients | |
DK0593562T3 (da) | Topisk præparat indeholdende penciclovir | |
NO984196L (no) | FremgangsmÕte for behandling av stoffmisbruk | |
Cutler et al. | Tolerability profiles of AChEIs: a critical component of care for Alzheimer's disease patients | |
ATE107504T1 (de) | Arzneimittel zur behandlung von kryptosporidiose. | |
TR200200111T2 (tr) | Neoplazmalar için terapötik ve profilaktik maddeler | |
Fann et al. | Halazepam in the treatment of recurrent anxiety attacks in chronically anxious outpatients: A double-blind placebo controlled study. |